top of page

Science, Women’s Health, and the Fight Against Misinformation [STAT Summit 2026 Review #33]

Nov 11
5 min read

Report 33. Science, Women’s Health, and the Fight Against Misinformation

Part I. English Version


1. Event / Date & Time

Event: Science, Women’s Health, and the Fight Against Misinformation | Sponsored by Bayer Pharmaceuticals

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 3:10 PM EDT


2. Participants

Speakers

- Kristie W. Baisden, D.O. — Vice President, U.S. Medical Affairs, Women’s Healthcare, Bayer Pharmaceuticals


Moderator

- Torie Bosch — Editor, First Opinion, STAT


3. Summary

Progress in Women’s Health: Menopause and contraception have gained new treatment options and renewed clinical attention, although access gaps persist.


Scientific Communication: Changing recommendations and historical limitations of evidence create challenges for public understanding and trust.


Countering Misinformation: Clinician education and clear discussion of benefits, risks and evolving evidence were emphasized as essential to informed decisions.


4. Main Discussion

Changing Menopause Care

Baisden recalled that menopause received limited attention in medical training two decades ago. She described growing availability of hormonal and nonhormonal options and mentioned new guidance from the American College of Obstetricians and Gynecologists released on the day of the session. The discussion framed updated professional guidance as an opportunity to improve care rather than evidence that every therapy is appropriate for everyone.

Baisden contrasted her own medical training two decades earlier with the recent expansion of professional attention to menopause. She said menopause had once received limited formal teaching and many patients were reluctant to initiate treatment. The conversation distinguished perimenopause from menopause and mentioned the clinical definition of twelve consecutive months without a menstrual period, with an average age around 51. Hormonal and nonhormonal therapies have expanded options, but changes in recommendations can be difficult for patients to interpret. Baisden referred to new professional guidance released by the American College of Obstetricians and Gynecologists on the day of the session. This was a discussion of trends in clinical guidance rather than a patient-specific treatment recommendation.

Baisden contrasted today’s menopause discussion with her own experience of medical training roughly two decades ago, when she said menopause management received comparatively little attention. She pointed to both hormonal and nonhormonal treatment options and described recent FDA and professional-society guidance as evidence of a more active clinical conversation. She also identified continued access barriers, so greater availability of therapies should not be confused with universal access to informed care. The timing of evolving clinical guidance matters because practitioners must translate updated evidence into conversations with patients who may have heard conflicting claims for years. Such translation requires acknowledging what recommendations changed and what clinical questions remain open.


Contraceptive Options and Access

The speaker noted progress in contraceptive choices, including long-acting methods, alongside continuing barriers to receiving appropriate care. She pointed out that innovation in products does not automatically remove access problems, particularly where patients lack reliable counseling and information.

Contraception was discussed as another field where product innovation and access do not always move together. More long-acting methods may expand individual choices, but patients still require reliable information, skilled counseling and practical access. Baisden drew on experience as an obstetrician-gynecologist, former FDA professional and industry medical-affairs leader to emphasize how evidence is translated differently in clinical practice, regulation and public communication. She suggested that patients’ histories and preferences should shape conversations rather than the assumption that everyone wishes to use the same method. The session’s patient-centered message was that science needs to be explained in language that supports informed choice, particularly when online narratives circulate faster than formal guidance.

The presentation gave concrete context for menopause definitions. Baisden cited an average age around 51 and the conventional definition of menopause as twelve consecutive months without menstruation. She emphasized that symptoms and care needs during perimenopause are not interchangeable with normal aging and may be interpreted differently by different patients. Clinical communication therefore needs to avoid attributing every symptom to one cause while also avoiding dismissal of symptoms that affect quality of life. Research opportunities include better characterization of symptom patterns, outcomes that matter to women and treatment effectiveness across groups not adequately represented in older studies.


Trust When Guidance Changes

Baisden discussed how emerging evidence can lead to revised recommendations that patients may experience as contradictory. Communicating what is known, what remains uncertain and why guidance evolves was described as important for maintaining trust in women’s healthcare.

A major communication challenge arises when recommendations change because evidence has improved. For some patients, a changed guideline appears to mean that science was unreliable before; clinicians may instead understand it as the expected result of learning from new data. Baisden stressed the need to describe not only what is recommended now but why prior guidance existed and what information altered the balance of benefits and risks. This is particularly relevant in menopause, where historical concerns about hormone treatment continue to influence discussion. She did not claim that every new treatment is appropriate for every woman. The session emphasized differentiated communication about symptoms, risks, preferences and evolving evidence to address misinformation without dismissing patient questions.

Contraception was discussed alongside menopause to show how medical options and public understanding can move at different speeds. Baisden referred to a wider range of products, including long-acting methods, but noted that access and counseling still shape patients’ actual choices. In reproductive health, trust can be undermined when advice appears inconsistent or when people perceive that important risks have not been explained. A clinician’s ability to discuss options without overstating certainty can therefore matter as much as adding another product to the market. This is relevant to drug developers preparing balanced educational materials and postmarketing information for women’s health therapies.


Addressing Misleading Health Narratives

The discussion emphasized the role of medical professionals and scientific organizations in answering questions about menopause, hormonal therapies and contraception. Consistent access to evidence-based information and respectful patient conversations were presented as practical responses to misinformation.

The speaker also identified persistent gaps in research attention and the delivery of women’s healthcare. A condition affecting many women can remain under-discussed when clinicians have limited training or when symptoms are normalized and not raised during visits. Improved guidelines and additional therapies may create opportunities, but implementation depends on physicians recognizing symptoms, presenting options and reaching women who do not routinely receive specialist care. In the sponsored discussion, scientific communication and commercial development were connected through the need for credible evidence and continuity of patient relationships. The broader implication was that sustained clinical education and public engagement are as necessary as individual product approvals.

The final emphasis was on countering misleading health claims through evidence and respectful dialogue. Baisden suggested that trust is harder to build through categorical reassurance than through acknowledging why recommendations change as studies accumulate. The session did not present a randomized evaluation of a particular misinformation intervention. Instead, it outlined the roles of clinicians, pharmaceutical medical affairs teams and professional organizations in making evidence understandable and accessible. The broader industrial lesson is that scientific evidence, medical communication and patient access are interconnected; neglecting any one of these components can limit the value of a new women’s health therapy.

Baisden emphasized shared decision-making because no two patients have identical contraception needs or experience perimenopause in exactly the same way. Listening without judgment and then describing the current evidence creates room for an individualized choice. This does not mean accepting every online claim as scientifically valid; it means understanding what the patient has heard and responding specifically to those concerns. For medical affairs and clinicians, the ability to explain how scientific guidance evolves is a continuing responsibility.


5. Insights

Evidence-Responsive Care: Women’s health R&D and guidelines should evolve with evidence while clearly communicating remaining uncertainties.


Implications for South Korea: Korea could examine clinician education and reliable public information channels for menopause and contraceptive care.


Trusted Health Networks: Coordination among professional societies, healthcare providers and patient communities may counter misinformation and improve informed access.



Comments


© 2026 KHIDI USA ALL RIGHT RESERVED

bottom of page